Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms’ tumor
Michael V. Ortiz(Memorial Sloan Kettering Cancer Center), Alex Kentsis(Memorial Sloan Kettering Cancer Center)
Cited by 29
Related Papers
Peptidomimetic blockade of MYB in acute myeloid leukemia
|Nature Communications|2018|95
Peptidomimetic blockade of MYB in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|11
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2017|8
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas
|Journal of Clinical Investigation|2025|4
Forward genetic screen of human transposase genomic rearrangements
|bioRxiv (Cold Spring Harbor Laboratory)|2016|0